



## Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2022

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- [Cue Biopharma, Inc.](#) (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body, announced today it will give a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in-person June 3–7 at the McCormick Place Convention Center in Chicago, Illinois and virtually.

The poster presents interim clinical data supporting the tolerability and antitumor activity of Cue Biopharma's lead interleukin 2 (IL-2)-based CUE-100 series therapeutic, CUE-101, both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®) for the treatment of patients with recurrent/metastatic HPV16+ head and neck cancer.

### Presentation Details:

**Title:** A Phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

**Abstract #: 6045**

**Presenter:** Dr. Christine Chung, M.D., Chair, Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa FL

**Date:** Monday, June 6, 2022, 1:15–4:15 p.m. CDT

The poster will be available in the Investor & Media section of the Company's website at [www.cuebiopharma.com](http://www.cuebiopharma.com) under Scientific Publications and Presentations, following the presentation.

### About ASCO

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. More than 40,000 oncology professionals from around the world convene at the ASCO Annual Meeting to share new clinical cancer advances in every area of cancer research, gain real-time insights from world-renown faculty, and connect with one of the largest, most diverse audiences in global oncology.

### About the CUE-100 Series

The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing the potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

### About Immuno-STAT

The company's Immuno-STAT™ (*Selective Targeting and Alteration of T cells*) biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a pMHC to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells. The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in selective T cell modulation. Because our drug candidates are delivered directly in the patient's body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients' T cells to be extracted, modified outside the body (ex vivo), and reinfused.

### About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary Immuno-STAT™ (*Selective Targeting and Alteration of T cells*) platform, is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Boston, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information, visit <https://www.cuebiopharma.com> and follow us on Twitter at <https://twitter.com/CueBiopharma>.

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the company's estimate of the period in which it expects to have cash to fund its operations; the company's belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the company's business strategies, plans and prospects. Forward-looking statements, which are based on certain

assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company's limited operating history, limited cash and a history of losses; the company's ability to achieve profitability; potential setbacks in the company's research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration ("FDA") or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the company's trials; negative or inconclusive results from the company's clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the future; operations and clinical the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

**Investor Contact**

Marie Campinell  
Senior Director, Corporate Communications  
Cue Biopharma, Inc.  
[mcampinell@cuebio.com](mailto:mcampinell@cuebio.com)

**Media Contact**

Maya Romanchuk, Ph.D.  
LifeSci Communications  
[mromanchuk@lifescicomms.com](mailto:mromanchuk@lifescicomms.com)



Source: Cue Biopharma, Inc.